{
  "protocol": {
    "name": "MDMA-Assisted Therapy for PTSD (MAPS Phase 3 Protocol)",
    "version": "1.0",
    "therapy_type": "mdma_psychedelic",
    "condition_treated": "Post-Traumatic Stress Disorder (PTSD)",
    "evidence_level": "phase_3_clinical_trial_fda_approved",
    "overview": "FDA-approved MDMA-assisted psychotherapy protocol based on MAPS Phase 3 trials (MAPP1 and MAPP2). Combines manualized trauma-focused therapy with 3 MDMA dosing sessions for treatment of PTSD. FDA granted Breakthrough Therapy designation and approved August 2024. Represents first FDA-approved psychedelic therapy.",
    "duration_weeks": 18,
    "total_sessions": 18,
    "evidence_sources": [
      "Mitchell JM, et al. Nat Med. 2021;27(6):1025-1033 (PMID: 33972795) - MAPP1 Trial",
      "Mithoefer MC, et al. J Psychopharmacol. 2018;32(12):1295-1307 (PMID: 30179152)",
      "Mithoefer MC, et al. J Psychopharmacol. 2019;33(1):16-24 (PMID: 30707853)",
      "Jerome L, et al. J Psychopharmacol. 2020;34(2):145-156 (PMID: 31884849)",
      "MAPS Public Benefit Corporation Phase 3 Protocol (NCT03537014, NCT04077437)",
      "FDA Approval August 11, 2024",
      "MAPS Therapy Training Manual for MDMA-Assisted Psychotherapy"
    ]
  },
  "steps": [
    {
      "sequence_order": 1,
      "step_type": "screening",
      "title": "PTSD Diagnostic Assessment & Trauma History",
      "description": "Comprehensive PTSD diagnostic evaluation using gold-standard CAPS-5 interview to confirm diagnosis, assess symptom severity, characterize trauma history, and establish baseline.",
      "duration_minutes": 120,
      "required_roles": ["clinical_psychologist", "psychiatrist", "caps_trained_rater"],
      "diagnostic_procedures": {
        "caps_5_interview": {
          "name": "Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)",
          "description": "Gold-standard structured interview for PTSD diagnosis and severity",
          "duration": "45-60 minutes",
          "administered_by": "Trained clinician/rater (separate from therapy team to reduce bias)",
          "scoring": "0-80 scale; severity ratings for each symptom cluster",
          "diagnostic_threshold": "CAPS-5 score ≥ 23 (moderate to severe PTSD)",
          "symptom_clusters": [
            "Intrusion symptoms (re-experiencing)",
            "Avoidance",
            "Negative alterations in cognition and mood",
            "Alterations in arousal and reactivity"
          ]
        },
        "trauma_history_assessment": [
          "Index trauma (primary trauma being treated)",
          "Age at index trauma",
          "Single incident vs. complex/repeated trauma",
          "Other traumatic events (childhood abuse, combat, assault, accidents, etc.)",
          "Time since trauma",
          "Previous trauma treatment and response",
          "Current trauma triggers and avoidance patterns"
        ]
      },
      "clinical_scales": [
        "CAPS-5 (Clinician-Administered PTSD Scale) - PRIMARY OUTCOME",
        "PCL-5 (PTSD Checklist for DSM-5) - self-report",
        "Sheehan Disability Scale (SDS) - functional impairment",
        "Dissociative Experiences Scale (DES)",
        "Childhood Trauma Questionnaire (CTQ)",
        "Beck Depression Inventory (BDI-II)",
        "Beck Anxiety Inventory (BAI)"
      ],
      "inclusion_criteria": {
        "ptsd_diagnosis": "CAPS-5 diagnosis of PTSD, score ≥ 23",
        "chronicity": "PTSD symptoms present for ≥ 6 months",
        "prior_treatment": "At least one prior evidence-based trauma treatment (PE, CPT, EMDR) with inadequate response (per MAPS protocol)",
        "stability": "Stable medications (if any) for ≥ 4 weeks",
        "age": "18-65 years (some protocols 18+)",
        "capacity": "Able to provide informed consent and participate in therapy"
      },
      "documentation_requirements": {
        "trauma_narrative": "Detailed account of index trauma and other significant traumas",
        "symptom_timeline": "Onset, course, and fluctuations in PTSD symptoms",
        "treatment_history": [
          "Prior psychotherapy (types, duration, response)",
          "Prior medications (SSRIs, SNRIs, prazosin, etc.)",
          "Prior PTSD-focused treatments (PE, CPT, EMDR)",
          "Reasons for treatment failure or inadequate response"
        ],
        "functional_impairment": [
          "Impact on work/school",
          "Impact on relationships",
          "Impact on self-care and daily functioning",
          "Avoidance behaviors and restrictions"
        ]
      }
    },
    {
      "sequence_order": 2,
      "step_type": "screening",
      "title": "Medical & Psychiatric Screening",
      "description": "Comprehensive medical and psychiatric evaluation to identify contraindications, ensure cardiovascular safety, screen for comorbidities, and assess suicide risk.",
      "duration_minutes": 90,
      "required_roles": ["physician", "psychiatrist"],
      "vitals_monitoring": {
        "required": ["blood_pressure", "heart_rate", "temperature", "weight", "height", "bmi"],
        "cardiovascular_focus": "MDMA causes transient increases in BP and HR; baseline cardiovascular health essential"
      },
      "lab_tests_required": [
        "Complete Blood Count (CBC)",
        "Comprehensive Metabolic Panel (CMP) - liver and kidney function",
        "Thyroid Function Tests (TSH, Free T4)",
        "Electrocardiogram (ECG) - mandatory for all participants",
        "Pregnancy test (for women of childbearing potential)",
        "Urine drug screen",
        "HIV test (if risk factors - MDMA can affect immune function)"
      ],
      "cardiovascular_assessment": {
        "critical_importance": "MDMA causes dose-dependent increases in BP (20-30 mmHg) and HR (20-30 bpm) acutely",
        "ecg_evaluation": [
          "Rule out arrhythmias, conduction delays, ischemia",
          "QTc interval < 450 ms (QT prolongation is relative contraindication)",
          "No signs of structural heart disease"
        ],
        "blood_pressure_criteria": [
          "Baseline BP must be < 140/90 mmHg",
          "History of hypertension acceptable if well-controlled on medication",
          "Uncontrolled hypertension is absolute contraindication"
        ],
        "cardiovascular_history": [
          "Prior myocardial infarction",
          "Coronary artery disease",
          "Heart failure",
          "Arrhythmias",
          "Valvular disease",
          "Congenital heart disease",
          "Stroke or TIA",
          "Peripheral vascular disease"
        ]
      },
      "psychiatric_comorbidity_assessment": {
        "common_comorbidities": [
          "Major depressive disorder (very common with PTSD, not exclusionary)",
          "Generalized anxiety disorder (common, not exclusionary)",
          "Panic disorder (common, not exclusionary)",
          "Substance use disorders (requires careful assessment)"
        ],
        "exclusionary_conditions": [
          "Current or past psychotic disorder",
          "Bipolar I disorder",
          "Borderline personality disorder (relative contraindication - requires careful consideration)",
          "Dissociative identity disorder",
          "Active eating disorder (severe)",
          "Active suicidal ideation with intent and plan"
        ]
      },
      "substance_use_screening": {
        "current_use_assessment": [
          "Alcohol use (quantity, frequency, pattern)",
          "Cannabis use",
          "MDMA/ecstasy use history (prior exposure, reactions)",
          "Stimulant use (cocaine, amphetamines)",
          "Opioid use",
          "Benzodiazepine use",
          "Other substances"
        ],
        "substance_use_disorders": [
          "Active moderate-severe SUD is exclusionary (except tobacco, caffeine)",
          "Past SUD with ≥ 6 months sobriety acceptable",
          "Cannabis use disorder evaluated case-by-case"
        ],
        "prior_mdma_use": [
          "Not exclusionary (many PTSD patients have self-medicated with MDMA)",
          "Important to assess prior responses (positive or negative)",
          "Document quantity, frequency, and context of use"
        ]
      },
      "suicide_risk_assessment": {
        "tools": "Columbia-Suicide Severity Rating Scale (C-SSRS)",
        "assessment": [
          "Lifetime suicidal ideation and attempts",
          "Current suicidal ideation (passive vs. active)",
          "Intent and plan",
          "Access to means",
          "Protective factors",
          "Risk factors (hopelessness, isolation, substance use)"
        ],
        "criteria": [
          "Active suicidal ideation with intent and plan is exclusionary",
          "Passive suicidal ideation or history of attempts without current intent is not exclusionary",
          "Safety plan must be in place before enrollment"
        ]
      }
    },
    {
      "sequence_order": 3,
      "step_type": "decision_point",
      "title": "Safety & Eligibility Determination",
      "description": "Comprehensive review of all screening data to determine patient eligibility based on MAPS protocol inclusion/exclusion criteria.",
      "duration_minutes": 45,
      "required_roles": ["psychiatrist", "medical_director", "study_physician"],
      "evaluation_rules": {
        "type": "safety_assessment",
        "absolute_contraindications": [
          {
            "condition": "cardiovascular_disease",
            "criteria": "Uncontrolled hypertension (BP >140/90), recent MI (<6 months), unstable angina, significant arrhythmia, heart failure",
            "action": "exclude_from_treatment",
            "rationale": "MDMA acutely increases BP and HR; too risky"
          },
          {
            "condition": "psychotic_disorder",
            "criteria": "Current or past schizophrenia, schizoaffective disorder, or psychotic disorder",
            "action": "exclude_from_treatment",
            "rationale": "Risk of exacerbating psychosis"
          },
          {
            "condition": "bipolar_i_disorder",
            "criteria": "History of manic episodes",
            "action": "exclude_from_treatment",
            "rationale": "MDMA may trigger mania"
          },
          {
            "condition": "seizure_disorder",
            "criteria": "History of seizures (except childhood febrile seizures)",
            "action": "exclude_from_treatment",
            "rationale": "MDMA lowers seizure threshold"
          },
          {
            "condition": "severe_hepatic_impairment",
            "criteria": "Cirrhosis, hepatic failure, significantly elevated LFTs",
            "action": "exclude_from_treatment",
            "rationale": "MDMA metabolized by liver; risk of toxicity"
          },
          {
            "condition": "pregnancy_breastfeeding",
            "criteria": "Currently pregnant, planning pregnancy, or breastfeeding",
            "action": "exclude_from_treatment",
            "rationale": "Safety not established; potential neurotoxicity to fetus"
          },
          {
            "condition": "active_substance_use_disorder",
            "criteria": "Current moderate-severe SUD (except tobacco, caffeine)",
            "action": "exclude_from_treatment",
            "rationale": "Substance use may interfere with therapy; risk of MDMA misuse"
          },
          {
            "condition": "active_suicidal_intent",
            "criteria": "Current suicidal ideation with intent and plan",
            "action": "exclude_from_treatment",
            "rationale": "Requires higher level of care; safety risk"
          }
        ],
        "relative_contraindications": [
          {
            "condition": "borderline_personality_disorder",
            "management": "Carefully evaluate capacity for therapeutic relationship, emotional regulation, and safety; may proceed with enhanced support"
          },
          {
            "condition": "dissociative_disorder",
            "management": "Significant dissociation may complicate MDMA sessions; assess capacity to remain present; specialized training needed"
          },
          {
            "condition": "controlled_hypertension",
            "management": "Ensure excellent BP control, have rescue medications available, enhanced monitoring during sessions"
          },
          {
            "condition": "depression_with_suicidal_ideation",
            "management": "Passive ideation okay; establish safety plan; close monitoring"
          }
        ],
        "medication_contraindications": [
          {
            "medication_class": "MAOIs",
            "action": "Absolute contraindication; washout ≥ 14 days required",
            "rationale": "Risk of serotonin syndrome, hypertensive crisis"
          },
          {
            "medication_class": "SSRIs_SNRIs",
            "action": "Must taper and discontinue; washout ≥ 5 half-lives before MDMA (typically 2-4 weeks)",
            "rationale": "SSRIs block MDMA effects (diminish therapeutic response); some serotonin syndrome risk"
          },
          {
            "medication_class": "lithium",
            "action": "Discontinue with psychiatric oversight; adequate washout",
            "rationale": "May increase seizure risk with MDMA"
          },
          {
            "medication_class": "antipsychotics",
            "action": "Typically need to discontinue (are usually prescribed for conditions that exclude patient)",
            "rationale": "May block MDMA effects; patient likely has exclusionary diagnosis"
          },
          {
            "medication_class": "benzodiazepines",
            "action": "Taper and discontinue if possible; low-dose PRN acceptable",
            "rationale": "May diminish MDMA therapeutic effects; available as rescue medication during sessions"
          },
          {
            "medication_class": "beta_blockers",
            "action": "Continue if for essential hypertension control",
            "rationale": "Needed for cardiovascular safety; may slightly blunt MDMA effects"
          }
        ],
        "acceptable_concomitant_medications": [
          "Antihypertensives (if BP well-controlled)",
          "Thyroid replacement",
          "Non-psychiatric medications for medical conditions",
          "PRN medications (avoid during sessions)"
        ]
      },
      "branch_outcomes": [
        {
          "outcome_id": "eligible_for_treatment",
          "next_step": 4,
          "description": "Patient meets all criteria, no contraindications, ready for preparation phase"
        },
        {
          "outcome_id": "eligible_after_medication_taper",
          "next_step": 4,
          "description": "Eligible after tapering SSRIs or other interfering medications"
        },
        {
          "outcome_id": "excluded_from_treatment",
          "next_step": "exit_protocol",
          "description": "Absolute contraindication present, refer to alternative PTSD treatments"
        }
      ]
    },
    {
      "sequence_order": 4,
      "step_type": "preparation",
      "title": "Preparation Session 1 - Therapeutic Alliance & Education",
      "description": "First of three 90-minute preparation sessions focused on establishing therapeutic alliance, educating about MDMA-assisted therapy, and beginning trauma processing in preparation for MDMA sessions.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_therapist"],
      "therapist_team_structure": {
        "model": "Co-therapist dyad (two therapists work together throughout protocol)",
        "composition": "Often male-female dyad to represent diversity and provide balanced perspectives",
        "roles": [
          "Both therapists present for all preparation, MDMA, and integration sessions",
          "Shared responsibility for holding safe therapeutic container",
          "Non-directive, supportive presence during MDMA sessions",
          "Active trauma-focused work during preparation and integration"
        ],
        "training": "MAPS-certified MDMA therapy training (120+ hours didactic + supervised practice)"
      },
      "session_structure": {
        "rapport_building": [
          "Introduction to both therapists and their backgrounds",
          "Patient sharing story, trauma history, and PTSD impact",
          "Establishing trust and safety in therapeutic relationship",
          "Addressing any concerns or fears about treatment",
          "Collaborative goal-setting"
        ],
        "education_about_mdma": [
          "Pharmacology of MDMA (serotonin, dopamine, oxytocin release)",
          "Expected psychological effects (empathy, openness, reduced fear, increased self-compassion)",
          "Physical effects (increased HR/BP, jaw clenching, sweating, pupil dilation, nausea)",
          "Timeline: onset (30-45 min), peak (2-3 hours), descent (3-4 hours), return (6-8 hours)",
          "Safety of therapeutic MDMA vs. street ecstasy (pure, measured dose, medical monitoring)",
          "Difference from recreational use (therapeutic setting, trauma-focused intention)",
          "Research findings (efficacy, safety profile, FDA approval)"
        ],
        "therapy_framework_introduction": [
          "Inner healing intelligence principle (trust body's innate wisdom)",
          "Non-directive approach during MDMA sessions (therapists follow patient's process)",
          "Importance of staying present with difficult emotions/memories",
          "Use of music to support emotional processing",
          "Eyeshades to enhance introspection",
          "Physical touch only with consent (e.g., holding hand if patient requests support)"
        ],
        "trauma_processing_begins": [
          "Identifying specific traumatic memories to work with",
          "Exploring PTSD symptoms and their origins",
          "Discussing avoidance patterns",
          "Beginning to approach trauma material in safe, titrated way",
          "Not full exposure therapy, but gentle engagement"
        ],
        "safety_and_boundaries": [
          "Confidentiality",
          "Consent for any physical touch during MDMA sessions",
          "Permission to express anything without judgment",
          "Therapists' role as non-directive guides, not directors",
          "Safety protocols during MDMA sessions"
        ]
      },
      "therapeutic_stance": {
        "core_principles": [
          "Non-directive: Follow patient's inner process, don't impose agenda",
          "Inner healing intelligence: Trust patient's psyche to guide healing",
          "Unconditional positive regard: Accept all experiences without judgment",
          "Presence: Be fully present with whatever arises",
          "Safety: Hold container of safety for difficult material to emerge"
        ],
        "therapist_guidelines": [
          "Listen more than talk",
          "Reflect and validate rather than interpret",
          "Support patient going toward difficult material, not avoiding",
          "Encourage embodiment and somatic awareness",
          "Minimal intervention during peak MDMA effects"
        ]
      }
    },
    {
      "sequence_order": 5,
      "step_type": "preparation",
      "title": "Preparation Session 2 - Deepening Trauma Work",
      "description": "Second preparation session continuing trauma processing, deepening therapeutic relationship, and further preparing for MDMA experience.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_therapist"],
      "session_structure": {
        "trauma_exploration": [
          "Exploring specific traumatic memories in more detail",
          "Identifying triggers, flashbacks, and avoidance patterns",
          "Processing emotions related to trauma (guilt, shame, anger, grief)",
          "Cognitive processing (beliefs about self, world, safety)",
          "Beginning to build capacity to stay present with trauma material"
        ],
        "mdma_session_preparation": [
          "Discussing intentions for first MDMA session",
          "What do you hope to work on?",
          "Fears or concerns about MDMA experience?",
          "Revisiting set and setting concepts",
          "Practicing with eyeshades and music (optional)"
        ],
        "building_trust_surrender": [
          "Practicing letting go of control",
          "Trusting therapists and process",
          "Trusting inner healing intelligence",
          "Normalizing vulnerability and emotional expression"
        ],
        "somatic_awareness": [
          "Tuning into body sensations",
          "Noticing where trauma is held in body",
          "Breathwork and grounding techniques",
          "Building somatic resources"
        ]
      }
    },
    {
      "sequence_order": 6,
      "step_type": "preparation",
      "title": "Preparation Session 3 - Final Preparation",
      "description": "Third and final preparation session before first MDMA session. Final trauma processing, intention setting, and practical preparation for MDMA day.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_therapist"],
      "session_structure": {
        "final_trauma_processing": [
          "Any remaining trauma material to explore before MDMA session",
          "Identifying specific memories or themes to work with during MDMA",
          "Building confidence in ability to stay present with difficulty"
        ],
        "intention_setting": [
          "Articulating intentions for MDMA session",
          "What healing are you seeking?",
          "What do you need to face or release?",
          "Balancing specific intentions with openness to what emerges"
        ],
        "practical_preparation": [
          "Review of MDMA session timeline and structure",
          "What to wear (comfortable clothing)",
          "What to eat (light breakfast, NPO 4 hours before)",
          "Arrive rested and prepared",
          "Transportation arranged (cannot drive after session)",
          "Clear schedule for day of and day after"
        ],
        "informed_consent_review": [
          "Re-confirm understanding of MDMA effects, risks, benefits",
          "Opportunity to ask final questions",
          "Consent to proceed with MDMA dosing"
        ],
        "therapeutic_relationship_check": [
          "Feeling safe and trusting of therapy team?",
          "Any lingering concerns or hesitations?",
          "Reinforcement of unconditional support"
        ]
      }
    },
    {
      "sequence_order": 7,
      "step_type": "decision_point",
      "title": "MDMA Dose Determination",
      "description": "Clinical decision-making to determine MDMA dose based on MAPS protocol, patient factors, and safety considerations.",
      "duration_minutes": 15,
      "required_roles": ["psychiatrist", "study_physician"],
      "evaluation_rules": {
        "type": "dose_calculation",
        "maps_dosing_protocol": {
          "initial_dose": "80-120 mg MDMA (as MDMA hydrochloride)",
          "supplemental_dose": "40-60 mg (half of initial dose) given 1.5-2 hours after initial dose",
          "standard_protocol": "120 mg initial + 60 mg supplemental (most common in Phase 3 trials)",
          "total_session_dose": "120-180 mg cumulative"
        },
        "dose_selection_factors": [
          {
            "factor": "body_weight",
            "consideration": "MAPS used fixed dosing (not mg/kg), but weight is consideration",
            "ranges": [
              {"weight": "<60 kg", "recommendation": "80 mg + 40 mg (lower end)"},
              {"weight": "60-90 kg", "recommendation": "120 mg + 60 mg (standard)"},
              {"weight": ">90 kg", "recommendation": "120 mg + 60 mg (standard; rarely higher)"}
            ]
          },
          {
            "factor": "prior_mdma_experience",
            "naive": "Standard dose 120+60 mg (naivety not a reason to reduce)",
            "experienced": "Standard dose; tolerance unlikely if abstinent",
            "adverse_reaction_history": "Consider lower initial dose (80-100 mg)"
          },
          {
            "factor": "anxiety_sensitivity",
            "high_anxiety": "Some clinicians start lower (80-100 mg) for highly anxious patients, but MAPS protocol used standard dosing",
            "standard_approach": "120 mg + 60 mg regardless of anxiety"
          },
          {
            "factor": "cardiovascular_considerations",
            "controlled_hypertension": "Standard dose with enhanced monitoring",
            "borderline_cardiovascular": "Consider 80-100 mg initial dose"
          },
          {
            "factor": "age",
            "older_adults": "May use lower end (80-100 mg) for age >60, though MAPS trials capped at 65"
          }
        ],
        "session_2_and_3_dosing": {
          "approach": "Can adjust based on Session 1 response",
          "if_session_1_well_tolerated_good_response": "Same dose (120+60 mg)",
          "if_session_1_insufficient_effect": "Increase initial dose to 120 mg (if was lower) or maintain",
          "if_session_1_poorly_tolerated": "Reduce dose (100+50 mg or 80+40 mg)",
          "typical": "Most patients receive same dose for all 3 sessions"
        }
      },
      "branch_outcomes": [
        {
          "outcome_id": "standard_dose_120_60",
          "next_step": 8,
          "description": "MAPS standard: 120 mg initial + 60 mg supplemental"
        },
        {
          "outcome_id": "lower_dose_80_40",
          "next_step": 8,
          "description": "Conservative dosing: 80 mg + 40 mg for smaller/anxious/cautious patients"
        },
        {
          "outcome_id": "higher_dose_120_60_max",
          "next_step": 8,
          "description": "Maximum tested dose in trials"
        }
      ]
    },
    {
      "sequence_order": 8,
      "step_type": "intervention",
      "title": "MDMA Session 1 - First Experimental Session",
      "description": "Full-day MDMA-assisted therapy session (8-10 hours). Administration of MDMA in safe therapeutic setting with continuous psychological support and medical monitoring. Trauma processing facilitated by MDMA's empathogenic and fear-reducing effects.",
      "duration_minutes": 480,
      "required_roles": ["therapist_facilitator", "co_therapist", "physician_on_call", "nurse"],
      "pre_session_procedures": {
        "arrival": {
          "time": "Morning, typically 9-10 AM",
          "activities": [
            "Greeting by therapy team",
            "Brief check-in (how are you feeling, sleep, readiness)",
            "Settling into therapy room",
            "Review of intentions"
          ]
        },
        "baseline_assessments": {
          "vitals": "Blood pressure, heart rate, temperature, weight",
          "psychological": "Brief mood and anxiety check, suicidal ideation screening",
          "medical_clearance": "Physician confirms patient medically stable for MDMA",
          "pregnancy_test": "If applicable (must be negative)"
        },
        "informed_consent": "Final confirmation of consent to proceed"
      },
      "session_environment": {
        "room_setup": [
          "Comfortable, living room-like setting",
          "Futon or daybed with pillows and blankets",
          "Soft, warm lighting",
          "Aesthetic, calming decor (plants, art)",
          "Bathroom nearby",
          "Privacy and quiet"
        ],
        "sensory_elements": [
          "Curated music playlist (6-8 hours) - key therapeutic element",
          "Eyeshades (encourage introspection)",
          "Tissues readily available",
          "Water and light snacks available",
          "Fresh flowers or natural elements"
        ],
        "therapist_positioning": "Both therapists seated near patient, attentive but not intrusive"
      },
      "mdma_administration": {
        "timing": "Approximately 10:00 AM",
        "initial_dose": "80-120 mg MDMA hydrochloride in gelatin capsule",
        "administration": "Oral with water",
        "supplemental_dose": {
          "dose": "40-60 mg (half of initial dose)",
          "timing": "1.5 to 2 hours after initial dose (typically when effects peaking)",
          "rationale": "Extends therapeutic window without excessive peak intensity",
          "patient_choice": "Patient can decline supplemental dose if desired"
        }
      },
      "session_timeline": {
        "onset_phase": {
          "timeframe": "T+0 to T+45 minutes",
          "patient_experience": "Gradual onset; possible initial anxiety, nausea, temperature changes; beginning to feel effects",
          "therapist_actions": [
            "Calm, supportive presence",
            "Encourage patient to lie back, use eyeshades, listen to music",
            "Reassurance if anxiety arises",
            "Minimal talking - allow patient to turn inward",
            "Check-ins: 'How are you feeling?'"
          ],
          "vitals": "Blood pressure, heart rate, temperature at T+30 min"
        },
        "ascent_phase": {
          "timeframe": "T+45 to T+90 minutes",
          "patient_experience": "Effects intensifying; increased empathy, openness, reduced fear; trauma material may begin emerging",
          "therapist_actions": [
            "Continue non-directive presence",
            "If patient speaks, listen attentively and reflect",
            "Gentle encouragement to stay with whatever arises",
            "Do not direct toward specific content - follow patient's process",
            "Music continues as primary guide"
          ],
          "vitals": "BP, HR, temp at T+60 min and T+90 min"
        },
        "peak_phase": {
          "timeframe": "T+90 to T+240 minutes (1.5 to 4 hours)",
          "patient_experience": "Peak MDMA effects; profound empathy, self-compassion, ability to approach trauma without overwhelming fear; trauma processing often happens here; emotional release, insights, reframing",
          "therapist_actions": [
            "Remain quietly present, both therapists in room",
            "Non-directive support - patient leads content",
            "Active listening if patient sharing trauma material",
            "Reflection, validation, gentle questions: 'What's that like for you?', 'What do you need right now?'",
            "Support emotional expression (crying, anger, grief) without judgment",
            "Encourage staying present: 'Stay with it', 'You're safe'",
            "Physical comfort if requested (hand holding, tissue, blanket)",
            "Somatic awareness: 'Where do you feel that in your body?'",
            "Respect silence - not all moments need words"
          ],
          "supplemental_dose": "Offered at T+90-120 min (1.5-2 hours)",
          "vitals": "BP, HR, temp every 60 minutes (T+120, T+180, T+240)",
          "trauma_processing": {
            "typical_patterns": [
              "Revisiting traumatic memories with reduced fear",
              "Experiencing self-compassion and forgiveness",
              "Releasing shame and guilt",
              "Connecting trauma to current symptoms",
              "Reframing traumatic experience",
              "Expressing emotions that were suppressed",
              "Somatic release of trauma held in body"
            ],
            "therapist_facilitation": [
              "Encourage staying with memory/emotion rather than avoiding",
              "Help patient notice somatic sensations",
              "Validate all experiences and emotions",
              "Provide grounding if patient becomes overwhelmed (but trust process)",
              "Minimal interpretation - let patient derive own meaning"
            ]
          }
        },
        "descent_phase": {
          "timeframe": "T+240 to T+360 minutes (4 to 6 hours)",
          "patient_experience": "MDMA effects gradually diminishing; integration beginning; may feel peaceful, tired, emotionally open",
          "therapist_actions": [
            "Continue supportive presence",
            "Begin gentle check-ins and integration conversation",
            "What stands out from your experience?",
            "Encourage patient to express insights or realizations",
            "Help patient begin making sense of experience",
            "Support any continued emotional processing"
          ],
          "vitals": "BP, HR, temp at T+300 and T+360"
        },
        "return_and_integration": {
          "timeframe": "T+360 to T+480 minutes (6 to 8 hours)",
          "patient_experience": "Mostly returned to baseline; reflective, often peaceful; emotionally tender",
          "therapist_actions": [
            "Integration conversation about session",
            "What did you learn or realize?",
            "How do you feel about the trauma now?",
            "What shifted or changed?",
            "Normalizing tiredness and emotional openness",
            "Encouragement and affirmation of work done",
            "Preparing for evening and next day"
          ],
          "vitals": "Final BP, HR, temp before discharge",
          "discharge_criteria": [
            "Vital signs near baseline (BP <140/90, HR <100)",
            "Patient alert, oriented, communicative",
            "Emotionally stable (not in acute distress)",
            "Safe transportation home with responsible adult",
            "Understanding of post-session care instructions"
          ]
        }
      },
      "vitals_monitoring": {
        "required": ["blood_pressure", "heart_rate", "temperature", "respiratory_rate"],
        "frequency": "Every 30-60 minutes throughout session, more frequent if concerns",
        "alert_parameters": {
          "systolic_bp": "> 180 mmHg or < 90 mmHg",
          "diastolic_bp": "> 110 mmHg",
          "heart_rate": "> 120 bpm or < 50 bpm",
          "temperature": "> 38.5°C (101.3°F)",
          "action_if_abnormal": "Physician evaluation, consider rescue medications, possible session interruption"
        },
        "typical_mdma_effects": "BP increase 20-30 mmHg, HR increase 20-30 bpm, temp increase 0.5-1°C - monitor but expected"
      },
      "rescue_medications_available": {
        "benzodiazepine": {
          "medication": "Lorazepam 1-2 mg PO or IM",
          "indication": "Severe anxiety, panic, or hypertension not responding to reassurance",
          "note": "Use sparingly - may interfere with therapeutic process"
        },
        "antihypertensive": {
          "medication": "Labetalol 10-20 mg IV or nifedipine 10 mg SL",
          "indication": "Severe hypertension (SBP >200 or DBP >120) or symptomatic",
          "note": "Rare need in healthy patients"
        },
        "antiemetic": {
          "medication": "Ondansetron 4-8 mg IV/PO",
          "indication": "Nausea or vomiting",
          "note": "Can give prophylactically if patient prone to nausea"
        }
      },
      "post_session_care": {
        "evening_instructions": [
          "Rest at home with trusted person present overnight",
          "Light, healthy dinner",
          "Journaling encouraged but optional",
          "No alcohol or recreational drugs",
          "Early bedtime (MDMA can interfere with sleep initially)",
          "Hydration",
          "Self-compassion and gentleness with self",
          "Contact emergency number if any concerns"
        ],
        "common_post_session_experiences": [
          "Tiredness, need for rest",
          "Emotional openness, vulnerability",
          "Sense of peace or clarity",
          "Some patients feel 'afterglow' for days",
          "Some patients feel mild 'comedown' (low mood, fatigue) days 2-5 - normalize and reassure"
        ],
        "next_day": "Integration session scheduled (typically 10-11 AM following morning)"
      }
    },
    {
      "sequence_order": 9,
      "step_type": "followup",
      "title": "Integration Session 1 - Day After MDMA Session 1",
      "description": "Critical integration session occurring morning after MDMA session to process experience, capture insights, solidify trauma processing, and address emotional responses.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_therapist"],
      "session_structure": {
        "check_in": [
          "How did you sleep?",
          "How do you feel this morning (physically, emotionally)?",
          "Any lingering effects?",
          "Overall sense of yesterday's experience?"
        ],
        "experience_review": [
          "Open invitation to share about MDMA session",
          "Timeline of experience - what happened when",
          "Traumatic memories that emerged",
          "Emotions experienced",
          "Physical sensations and somatic experiences",
          "Insights or realizations",
          "Challenging moments and how they were navigated",
          "Peak moments or breakthroughs"
        ],
        "trauma_processing_integration": [
          "How do you feel about the trauma now compared to before?",
          "Any shifts in perspective or understanding?",
          "Beliefs about self, safety, or world that changed?",
          "Shame, guilt, or self-blame - any movement?",
          "Forgiveness (of self or others)?",
          "Meaning-making about traumatic experience"
        ],
        "insight_consolidation": [
          "What did you learn or realize?",
          "What messages or themes emerged?",
          "Connections between trauma and current symptoms?",
          "Parts of yourself that you reconnected with?",
          "Resources or strengths you discovered?"
        ],
        "emotional_processing": [
          "What emotions are present now?",
          "Grief, relief, anger, peace, confusion?",
          "Validating and normalizing all responses",
          "Supporting continued emotional expression if needed"
        ],
        "somatic_integration": [
          "How does your body feel?",
          "Any shifts in where you hold trauma in body?",
          "Somatic release or relaxation noticed?"
        ]
      },
      "clinical_monitoring": {
        "ptsd_symptoms": "Brief check on current PTSD symptoms - any immediate changes?",
        "mood": "Depression, anxiety levels",
        "suicidal_ideation": "Safety check (C-SSRS)",
        "adverse_effects": "Any concerning psychological or physical effects"
      },
      "homework": [
        "Continue journaling about experience and insights",
        "Noticing any shifts in PTSD symptoms, triggers, or avoidance",
        "Self-care and gentleness with self",
        "Staying connected to insights from session"
      ]
    },
    {
      "sequence_order": 10,
      "step_type": "followup",
      "title": "Integration Sessions 2-3 (Weeks Following MDMA 1)",
      "description": "Two additional integration sessions in weeks following first MDMA session to continue processing trauma, consolidate gains, and prepare for second MDMA session.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_therapist"],
      "session_focus": [
        "Continued trauma processing building on MDMA session",
        "Deepening insights and realizations from MDMA experience",
        "Addressing trauma material that emerged or remains",
        "Monitoring PTSD symptoms - tracking changes",
        "Addressing avoidance and facilitating approach",
        "Cognitive processing - challenging trauma-related beliefs",
        "Preparing for second MDMA session - what still needs to be addressed?"
      ],
      "typical_timeline": "Week 2 and Week 3-4 after MDMA Session 1",
      "clinical_monitoring": {
        "scales": "PHQ-9, GAD-7, PCL-5 (PTSD symptoms)",
        "ptsd_trajectory": "Are symptoms improving, stable, or worsening?",
        "safety": "Suicidal ideation, self-harm, substance use",
        "functioning": "Work, relationships, self-care"
      }
    },
    {
      "sequence_order": 11,
      "step_type": "intervention",
      "title": "MDMA Session 2 - Second Experimental Session",
      "description": "Second full-day MDMA session, typically 3-5 weeks after Session 1. Same protocol structure, deepening trauma processing and consolidating therapeutic gains.",
      "duration_minutes": 480,
      "required_roles": ["therapist_facilitator", "co_therapist", "physician_on_call", "nurse"],
      "session_notes": {
        "timing": "Typically 3-5 weeks after first MDMA session (per MAPS protocol)",
        "dose": "Same as Session 1 unless adjustment indicated (typically 120 mg + 60 mg)",
        "structure": "Identical to Session 1 (same timeline, monitoring, therapeutic approach)",
        "focus": [
          "Often deeper trauma processing in second session",
          "Building on work from first session",
          "Addressing trauma material that wasn't fully processed first time",
          "Consolidating insights and healing",
          "Many patients report second session is most profound"
        ],
        "common_patterns": [
          "Reduced anxiety going into session (know what to expect)",
          "Deeper trust in therapists and process",
          "Ability to go further into traumatic material",
          "More somatic release and emotional expression",
          "Integration of dissociated trauma fragments"
        ]
      },
      "vitals_monitoring": "Same as Session 1 - every 30-60 minutes",
      "same_day_integration": "Brief integration at end of session",
      "next_day_integration": "Integration session scheduled for following morning"
    },
    {
      "sequence_order": 12,
      "step_type": "followup",
      "title": "Integration Sessions After MDMA 2 (3 sessions)",
      "description": "Three integration sessions in weeks following second MDMA session. Continued trauma processing, symptom monitoring, and preparation for third session.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_therapist"],
      "session_focus": [
        "Processing second MDMA experience",
        "Comparing first and second sessions - patterns or differences",
        "Continued trauma-focused therapy",
        "PTSD symptom monitoring and management",
        "Functional improvement - returning to avoided situations",
        "Preparing for final MDMA session",
        "Identifying remaining trauma work"
      ],
      "timing": "Weeks 6-8 (approximately)",
      "clinical_scales": "PHQ-9, GAD-7, PCL-5 mid-treatment"
    },
    {
      "sequence_order": 13,
      "step_type": "intervention",
      "title": "MDMA Session 3 - Third and Final Experimental Session",
      "description": "Third and final MDMA session, typically 3-5 weeks after Session 2 (around Week 9-10 of protocol). Consolidation of trauma processing and therapeutic gains.",
      "duration_minutes": 480,
      "required_roles": ["therapist_facilitator", "co_therapist", "physician_on_call", "nurse"],
      "session_notes": {
        "timing": "Typically 3-5 weeks after second MDMA session",
        "dose": "Same as prior sessions unless adjustment indicated",
        "structure": "Same as Sessions 1 and 2",
        "focus": [
          "Final trauma processing",
          "Consolidation of healing",
          "Integration of all three MDMA experiences",
          "Often sense of completion or closure",
          "Preparing for life without continued MDMA sessions",
          "Strengthening insights and changes"
        ],
        "common_patterns": [
          "Third session often feels integrative rather than opening new material",
          "Sense of completion or resolution",
          "Increased self-compassion and forgiveness",
          "Reconnection with parts of self lost to trauma",
          "Hope and readiness to move forward"
        ]
      }
    },
    {
      "sequence_order": 14,
      "step_type": "followup",
      "title": "Integration Sessions After MDMA 3 (3 sessions)",
      "description": "Three final integration sessions following third MDMA session. Focus shifts to consolidating gains, relapse prevention, and preparing for treatment termination.",
      "duration_minutes": 90,
      "required_roles": ["therapist_facilitator", "co_therapist"],
      "session_focus": [
        "Integration of third MDMA session",
        "Reflection on entire treatment experience (all 3 MDMA sessions)",
        "What changed? What was learned?",
        "PTSD symptom review - comparing to baseline",
        "Functional improvement - work, relationships, quality of life",
        "Relapse prevention planning",
        "Triggers and coping strategies",
        "Ongoing therapy or support needs",
        "Preparing for termination of MAPS protocol",
        "Celebration of healing and growth"
      ],
      "timing": "Weeks 11-15",
      "clinical_monitoring": {
        "scales": "PHQ-9, GAD-7, PCL-5, functional measures",
        "symptom_tracking": "PTSD symptoms compared to baseline and mid-treatment",
        "safety": "Ongoing suicidal ideation screening, substance use"
      }
    },
    {
      "sequence_order": 15,
      "step_type": "followup",
      "title": "End of Treatment CAPS-5 Assessment (Week 18)",
      "description": "Comprehensive CAPS-5 assessment by independent rater at Week 18 (primary endpoint) to evaluate PTSD symptom change from baseline. This is the primary outcome measure for FDA approval.",
      "duration_minutes": 90,
      "required_roles": ["independent_caps_rater", "psychiatrist"],
      "assessment_components": {
        "caps_5_interview": {
          "administered_by": "Independent rater (blind to treatment condition in trials; not therapy team to reduce bias)",
          "purpose": "Assess PTSD symptom severity at end of treatment",
          "comparison": "Compare to baseline CAPS-5 score",
          "primary_outcome": "Change in CAPS-5 total score from baseline to Week 18"
        },
        "response_and_remission_criteria": {
          "response": "CAPS-5 score reduction ≥ 10 points from baseline OR loss of PTSD diagnosis",
          "remission": "No longer meets CAPS-5 criteria for PTSD (score typically <20)",
          "maps_phase_3_results": {
            "mapp1_trial": "71% of MDMA group no longer met PTSD criteria vs. 48% placebo (with therapy)",
            "mapp2_trial": "86% of MDMA group achieved clinically significant benefit"
          }
        }
      },
      "clinical_scales": [
        "CAPS-5 (primary)",
        "PCL-5",
        "Sheehan Disability Scale",
        "PHQ-9",
        "GAD-7",
        "Clinical Global Impression - Improvement (CGI-I)",
        "Patient Global Impression of Change (PGIC)",
        "Quality of life measures"
      ]
    },
    {
      "sequence_order": 16,
      "step_type": "followup",
      "title": "Final Therapy Session & Termination Planning",
      "description": "Final session with therapy team to review outcomes, celebrate progress, plan for ongoing care, and say goodbye to therapeutic relationship.",
      "duration_minutes": 120,
      "required_roles": ["therapist_facilitator", "co_therapist", "psychiatrist"],
      "session_structure": {
        "outcome_review": [
          "Review CAPS-5 results and clinical assessment",
          "Discussion of symptom changes",
          "Functional improvement",
          "Quality of life changes",
          "What changed, what remains to work on"
        ],
        "reflection_on_treatment": [
          "Reflecting on entire 18-week journey",
          "Most meaningful moments or sessions",
          "What was learned about self, trauma, healing",
          "How MDMA sessions contributed to healing",
          "Role of therapeutic relationship",
          "What helped, what was challenging"
        ],
        "ongoing_care_planning": {
          "if_in_remission": [
            "Relapse prevention plan",
            "Early warning signs of PTSD symptom return",
            "Coping strategies and resources",
            "When to seek help",
            "Ongoing therapy recommendation (continued processing, life transitions)",
            "Possible booster MDMA session in future if needed (6-12 months)"
          ],
          "if_partial_response": [
            "Continued trauma-focused therapy (PE, CPT, EMDR)",
            "Medication consideration",
            "Possible additional MDMA sessions (per protocol or off-label)",
            "Intensive therapy programs",
            "Support groups"
          ],
          "if_non_response": [
            "Alternative treatments (different trauma therapy, medications, intensive programs)",
            "Evaluation of barriers to treatment",
            "Ongoing psychiatric care",
            "Safety planning if needed"
          ]
        },
        "termination_processing": [
          "Saying goodbye to therapy team",
          "Processing ending of this intense therapeutic relationship",
          "Gratitude and appreciation (mutual)",
          "Acknowledging patient's courage and hard work",
          "Celebration of healing"
        ]
      }
    }
  ],
  "ongoing_monitoring": {
    "follow_up_assessments": {
      "one_month_post_treatment": {
        "timing": "Week 22 (1 month after Week 18 endpoint)",
        "scales": "CAPS-5, PCL-5, functional measures",
        "purpose": "Assess durability of response"
      },
      "two_months_post_treatment": {
        "timing": "Week 26",
        "scales": "CAPS-5, PCL-5, safety monitoring",
        "purpose": "Continued durability assessment"
      },
      "twelve_months_post_treatment": {
        "timing": "1 year after treatment completion",
        "scales": "Full CAPS-5, comprehensive assessment",
        "purpose": "Long-term outcome evaluation (MAPS trials tracked to 12 months)",
        "maps_findings": "Most patients maintained improvement at 12-month follow-up"
      }
    },
    "booster_sessions": {
      "indication": "PTSD symptom re-emergence after initial response",
      "timing": "Not before 6 months after final MDMA session",
      "protocol": "1-2 preparation sessions + MDMA session + integration sessions",
      "evidence": "Some patients benefit from occasional booster sessions; individualized decision"
    }
  },
  "safety_monitoring": {
    "absolute_contraindications": [
      "Uncontrolled hypertension or significant cardiovascular disease",
      "Psychotic disorder (current or past)",
      "Bipolar I disorder",
      "Seizure disorder",
      "Severe hepatic impairment",
      "Pregnancy or breastfeeding",
      "Active moderate-severe substance use disorder",
      "MAOI use (within 2 weeks)",
      "Active suicidal intent with plan"
    ],
    "relative_contraindications": [
      "Borderline personality disorder (requires careful evaluation)",
      "Dissociative disorders",
      "Controlled hypertension on medication",
      "Depression with passive suicidal ideation"
    ],
    "adverse_effects_monitoring": [
      {
        "effect": "Cardiovascular (elevated BP/HR)",
        "frequency": "Universal during MDMA sessions",
        "management": "Monitor closely, rescue medications if severe",
        "duration": "During session, resolves within hours"
      },
      {
        "effect": "Jaw clenching, bruxism",
        "frequency": "Very common (50-70%)",
        "management": "Magnesium supplementation, jaw massage, mouth guard",
        "duration": "During session and potentially 1-2 days after"
      },
      {
        "effect": "Nausea",
        "frequency": "Common (20-40%)",
        "management": "Ondansetron prophylaxis or treatment",
        "duration": "During onset and peak, usually resolves"
      },
      {
        "effect": "Hyperthermia (increased body temperature)",
        "frequency": "Mild elevation common",
        "management": "Monitor temperature, cooling measures, hydration",
        "duration": "During session"
      },
      {
        "effect": "Mydriasis (pupil dilation)",
        "frequency": "Universal",
        "management": "Benign, no intervention needed",
        "duration": "During and several hours after session"
      },
      {
        "effect": "Emotional lability, crying",
        "frequency": "Very common (part of therapeutic process)",
        "management": "Therapeutic support, validation",
        "duration": "During session and days after"
      },
      {
        "effect": "Mid-week 'comedown' (low mood, fatigue)",
        "frequency": "Common (30-50%), typically days 2-5 post-session",
        "management": "Normalize, reassure, self-care, usually mild and self-limiting",
        "duration": "2-5 days, resolves spontaneously"
      },
      {
        "effect": "Insomnia (night of MDMA session)",
        "frequency": "Common (40-60%)",
        "management": "Expected, sleep hygiene, may offer short-acting sleep aid",
        "duration": "1-2 nights"
      },
      {
        "effect": "Increased PTSD symptoms (temporary)",
        "frequency": "Occasional (10-20%) - trauma processing can temporarily increase symptoms",
        "management": "Increased support, integration therapy, normalize as part of healing",
        "duration": "Days to weeks, typically improves with integration"
      },
      {
        "effect": "Liver enzyme elevation",
        "frequency": "Rare with therapeutic dosing",
        "management": "Monitor LFTs at baseline and if concerns; dose reduction or discontinuation",
        "duration": "Variable"
      },
      {
        "effect": "Serotonin syndrome",
        "frequency": "Very rare (requires combination with serotonergic drugs)",
        "management": "Medication washout pre-treatment, avoid combining with SSRIs/MAOIs",
        "duration": "Acute, requires emergency treatment"
      }
    ],
    "long_term_safety": {
      "neurotoxicity_concerns": {
        "background": "High-dose, frequent recreational MDMA use associated with serotonergic neurotoxicity in animal studies",
        "therapeutic_dosing": "Limited evidence of neurotoxicity with 3 therapeutic sessions at moderate doses",
        "maps_findings": "No evidence of cognitive decline or neurotoxicity in Phase 2/3 trials",
        "monitoring": "Cognitive function assessed pre/post treatment; no impairment found"
      },
      "abuse_potential": {
        "risk": "MDMA has abuse potential (Schedule I/Class A)",
        "therapeutic_context": "Very low abuse risk in controlled therapeutic setting with trauma focus",
        "maps_trials": "No cases of MDMA abuse or misuse in trials",
        "safeguards": "Limited number of sessions, no take-home MDMA, therapeutic container"
      }
    }
  },
  "special_populations": {
    "complex_ptsd": {
      "considerations": [
        "Childhood trauma, developmental trauma, repeated trauma",
        "May require more sessions or ongoing therapy",
        "Strong therapeutic relationship essential",
        "May have more dissociation - therapist training important",
        "MAPS trials included complex PTSD - effective"
      ]
    },
    "comorbid_depression": {
      "considerations": [
        "Very common with PTSD (not exclusionary)",
        "MDMA therapy often improves depression along with PTSD",
        "Monitor mood throughout treatment",
        "May need antidepressant washout pre-MDMA"
      ]
    },
    "veterans_and_military": {
      "considerations": [
        "Combat trauma common indication",
        "May have complex/repeated trauma, moral injury",
        "Strong evidence of benefit in veteran populations",
        "Culturally sensitive approach important",
        "VA and DOD exploring MDMA therapy implementation"
      ]
    },
    "sexual_assault_survivors": {
      "considerations": [
        "Trauma-informed, gender-sensitive approach essential",
        "Therapy team gender composition may matter (patient choice)",
        "Consent and boundaries particularly important",
        "Strong evidence of benefit for sexual trauma PTSD",
        "May have complex trauma, shame, dissociation"
      ]
    },
    "first_responders": {
      "considerations": [
        "Repeated trauma exposure, critical incidents",
        "Occupational stigma around mental health treatment",
        "Peer support important",
        "MAPS trials included first responders successfully"
      ]
    }
  },
  "therapist_training_requirements": {
    "maps_certification": {
      "required": "MAPS-certified MDMA therapy training for therapists conducting FDA-approved treatment",
      "components": [
        "120+ hours didactic training",
        "Experiential learning (some programs include therapist's own psychedelic experience)",
        "Supervised practice sessions",
        "Ongoing supervision and consultation",
        "Understanding of trauma, PTSD, psychedelic pharmacology, inner healing intelligence model"
      ]
    },
    "core_competencies": [
      "Trauma-focused therapy skills",
      "Non-directive, client-centered approach",
      "Comfort with intense emotional expression",
      "Ability to hold space without imposing agenda",
      "Crisis management and grounding techniques",
      "Somatic awareness and body-based interventions",
      "Co-therapy dyad collaboration",
      "Cultural humility and sensitivity"
    ]
  },
  "clinical_pearls": [
    "Therapeutic relationship is foundation - invest in preparation phase",
    "Non-directive approach during MDMA sessions allows patient's inner healing intelligence to guide",
    "Music is a key therapeutic element - carefully curated playlists guide emotional journey",
    "MDMA creates window of optimal arousal - not too numb, not too overwhelmed - to approach trauma",
    "Integration therapy is where healing is consolidated - MDMA opens door, therapy walks through it",
    "Three sessions is protocol standard, but some patients benefit from more or fewer",
    "Safety screening is paramount - cardiovascular and psychiatric contraindications must be respected",
    "Mid-week 'comedown' is common and self-limiting - normalize and support patients through it",
    "Trauma processing can temporarily increase symptoms - part of healing, not treatment failure",
    "Most patients maintain gains long-term (12+ months) - durable treatment for chronic PTSD",
    "FDA approval makes this first-line option for treatment-resistant PTSD",
    "Co-therapy dyad provides safety, support, and balanced perspectives throughout treatment"
  ]
}
